Antisense oligonucleotide therapy for triglyceride reduction shows positive top-line results

Akcea Therapeutics and Ionis Pharmaceuticals announced that a phase 2 study of AKCEA-ANGPTL3-LRx for the treatment of patients with hypertriglyceridemia, type 2 diabetes and nonalcoholic fatty liver disease met its primary endpoint of significant triglyceride lowering.The study also met several secondary endpoints with a favorable tolerability and safety profile, according to a press release from the companies.AKCEA-ANGPTL3-LRx is an antisense oligonucleotide therapy that reduces production of angiopoietin-like 3 (ANGPTL3) protein in the liver.The phase 2 study aimed to evaluate the efficacyRead More

Share on facebook
Share on twitter
Share on linkedin